EGFR and non-small cell lung carcinoma: In metastatic stage settings, the appearance of T790M mutation after resistance to initial EGFR-TKI treatment (acquired T790M) has been reported to be associated with a good prognosis in the patients with EGFR-mutated NSCLC [22, 38, 39].